How Effective Is Stelara for Crohn's Disease?
Stelara (ustekinumab) treats moderate to severe Crohn's disease in adults and children 6+ who haven't responded well to other therapies like steroids or immunomodulators. It targets interleukins 12 and 23, reducing gut inflammation.[1]
In the pivotal UNITI-1 and UNITI-2 phase 3 trials, 50-60% of patients achieved clinical remission (CDAI score under 150) at week 8 after a single IV dose, compared to 35% on placebo. By week 52 with subcutaneous maintenance doses, remission rates held at 44-53% versus 18-21% on placebo.[2][3]
Real-world data shows sustained response: about 70% of patients maintain remission after one year, with many avoiding surgery or hospitalization.[4]
What Do Long-Term Studies Show?
The IM-UNITI maintenance trial extension tracked patients up to 3 years. Around 48% stayed in remission at year 3 with every-8-week dosing, and 38% with every-12-week dosing. Endoscopic improvement (SES-CD score drop of 50%+) occurred in 40-50% of responders.[2][5]
Five-year data from open-label extensions report 60%+ clinical response rates, with low immunogenicity (antibodies in <10%, rarely neutralizing).[6]
How Does Stelara Compare to Humira or Inflectra?
Stelara outperforms TNF inhibitors like Humira (adalimumab) in head-to-head trials. In SEAVUE, 81% of Stelara patients had no treatment failure at week 48, versus 69% on anti-TNFs; serious adverse events were lower (5% vs 11%).[7]
Against Inflectra (infliximab biosimilar), Stelara showed higher week-52 remission (47% vs 38%) in Crohn's patients switching therapies.[8]
| Drug | Week 8 Remission | Week 52 Remission | Surgery-Free Rate (1 Year) |
|------|------------------|-------------------|----------------------------|
| Stelara | 51-55% | 44-53% | 95%+ |
| Humira | 40-50% | 30-40% | 90% |
| Infliximab | 45% | 35-40% | 92% |
When Do Patients See Results, and How Long Do They Last?
Symptom relief (stool frequency, pain) starts in 2-6 weeks for most. Full remission by week 8 in responders. Benefits persist 3-5 years in 40-60%, though 20-30% lose response yearly, often regaining it with dose escalation.[4][6]
What About Fistulizing Crohn's?
In patients with draining fistulas, 59% achieved fistula remission at week 44 (vs 43% placebo), with 50%+ closure by year 1—better than anti-TNFs alone (30-40%).[2]
Common Patient Concerns on Effectiveness
Loss of response affects 20-30% over time due to antibodies or disease progression. It's more effective in biologic-naive patients (60% remission) than those previously on anti-TNFs (40%). No data on patent expiry impacts access yet—Janssen's key patents expire 2023-2030 in major markets.[9][DrugPatentWatch.com]
[1]: FDA Stelara Label (2023) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761044s029lbl.pdf
[2]: Feagan et al., NEJM (2016) - UNITI trials
[3]: Sandborn et al., Gastroenterology (2017)
[4]: Alric et al., Aliment Pharmacol Ther (2021) - real-world cohort
[5]: Adedokun et al., J Crohns Colitis (2019)
[6]: Sandborn et al., Gastroenterology (2021) - 5-year data
[7]: Sandborn et al., Gastroenterology (2023) - SEAVUE
[8]: Switch study, Colombel et al., Clin Gastroenterol Hepatol (2022)
[9]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/STELARA